A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).

Authors

Adrienne Gropper Waks

Dana-Farber Cancer Institute, Boston, MA

Adrienne Gropper Waks , Tanya Keenan , Tianyu Li , Nabihah Tayob , Gerburg M. Wulf , Edward T. Richardson III, Elizabeth A. Mittendorf , Beth Overmoyer , Ian E. Krop , Eric P. Winer , Eliezer Mendel Van Allen , Judith Agudo , Sara M. Tolaney

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT03032107

Citation

J Clin Oncol 38: 2020 (suppl; abstr 1046)

DOI

10.1200/JCO.2020.38.15_suppl.1046

Abstract #

1046

Poster Bd #

131

Abstract Disclosures

FEATURED

A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).

Authors

Adrienne Gropper Waks

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Retrospective observational study of outcomes in HER2-positive metastatic breast cancer patients treated with trastuzumab emtansine in single center.

Poster

Poster

Halo 110-101: Early safety results of pegvorhyaluronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) ± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC).

Poster

NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC).